Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2015

01-05-2015 | Erratum

Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry

Authors: Eric Rosenthal, Kelsey Moyes, Christopher Arnell, Brent Evans, Richard J. Wenstrup

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Excerpt

In Table 2 of the original publication, the HGVS and legacy nomenclature were mismatched and the HGVS nomenclature did not correlate with data listed in the table. The corrected table is listed below.
Table 2
Distribution of non-founder mutations in patients of Ashkenazi Jewish and other ancestries
Gene
Mutationa
Total (all ancestries)b
AJ ancestry only (%)c
Partial AJ ancestry (%)d
All or partial AJ ancestry (%)e
BRCA2
c.3847_3848del (4075delGT)
321
15 (4.7)
6 (1.9)
21 (6.5)
BRCA2
c.1754del (1982delA)
10
7 (70.0)
1 (10.0)
8 (80.0)
BRCA1
c.4936del (5055delG)
21
7 (33.3)
2 (9.5)
9 (42.9)
BRCA2
c.9382C>T (R3128X)
227
7 (3.1)
4 (1.8)
11 (4.8)
BRCA2
c.4829_4830del (5057delTG)
27
6 (22.2)
5 (18.5)
11 (40.7)
BRCA2
c.2808_2811del (3036del4)
460
6 (1.3)
6 (1.3)
12 (2.6)
aMutations are listed with HGVS nomenclature, and the legacy nomenclature in parentheses
bNumber of finds in patients of all ancestries for whom full sequencing was performed January 2006 through August 2013
cNumber and percentage of all finds in patients for whom only AJ ancestry was reported
dNumber and percentage of all finds in patients for whom AJ ancestry was reported in conjunction with one or more additional ancestries
eNumber and percentage of all finds in patients for whom either full or partial AJ ancestry was reported
Metadata
Title
Erratum to: Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry
Authors
Eric Rosenthal
Kelsey Moyes
Christopher Arnell
Brent Evans
Richard J. Wenstrup
Publication date
01-05-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3361-z

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine